Radicava Will Be a New Specialty Med for Lou Gehrig's Disease

Radicava (ra-dih-CAH-vah, edaravone) is the first med approved for Lou Gehrig's disease, or ALS, in almost 20 years.

Until now, we've only had riluzole (Rilutek) to treat this progressive, degenerative nerve disease...which eventually leads to muscle weakness, paralysis, and death.

Radicava helps slow the decline in physical function...such as speech, salivation, and swallowing.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote